ReviewFrontiers in immunology2025
A case report of eosinophilic granulomatosis with polyangiitis in children with cerebella infarction as the first symptom and literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This case report presents a pediatric case of eosinophilic granulomatosis with polyangiitis (EGPA) presenting with cerebella infarction as the initial symptom. The study aims to summarize the clinical features and treatment advancements of this condition, enhancing clinicians 'understanding and reducing misdiagnosis and missed diagnosis. Methods: A 9-year-old male patient admitted to the Rheumatology Department of Anhui Provincial Children's Hospital was evaluated for "Dizziness, vomiting for one day, and consciousness impairment for half a day." The patient had recurrent bilateral lower limb rashes and asthma attacks over the past year. Blood tests revealed elevated eosinophil levels and IgE antibodies, while bone marrow cytology showed increased eosinophil counts. Brain MRI demonstrated cerebral infarction, herniation, and suspected thrombosis, with skin biopsy confirming vasculitis characteristics. Through retrospective analysis of clinical data and literature review, this study comprehensively summarizes EGPA's clinical features and treatment progress. Results: The patient presented with cerebella infarction as the initial symptom, accompanied by central nervous system involvement, skin manifestations, hematological disorders, and vasculitis. With a history of asthma attacks, eosinophil counts during hospitalization peaked at 4.9×10^9/L (compared to baseline levels>1×10^9/L). After thorough evaluation for infections, malignancies, diffuse connective tissue diseases, immunodeficiency disorders, and inherited metabolic disorders, EGPA was confirmed. Treatment included anti-inflammatory steroids, cyclophosphamide (CTX) induction therapy, anticoagulation, followed by mycophenolate mofetil (MMF) maintenance at therapeutic doses, supplemented with rituximab. Current follow-up shows normalized eosinophil counts, restored muscle strength, resolution of skin rashes without recurrence, and favorable clinical response. Conclusion: EGPA presents diverse clinical features. Cerebella infarction as the first neurological manifestation in children is rare. Eosinophilia serves as a characteristic feature. When pediatric asthma patients exhibit neurological symptoms, EGPA should be considered. For cases with central nervous system involvement, combined steroid therapy with cyclophosphamide pulse induction proves effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.